Email this article The Correlation of Treg Cells (CD4+CD25+) with Viral Load between HIV Patients and TB-HIV Patients in Semarang Indonesia
Abstract
The number of HIV-AIDS patients in Indonesia has considerably increased. The life expectancy of HIV-AIDS patients gets longer in the presence of antiretroviral treatment (ARV). Most opportunistic infections of HIV infection are found to be Tuberculosis (TB-HIV). Antiretroviral and anti-tuberculosis treatment will improve the quality of life of people living with HIV-AIDS (PLWHA). Regulatory T cells (Tregs) were suggested to play a role in immune response of HIV and TB-HIV. This study aims to investigate the response of Tregs of patients with HIV and TB-HIV, their clinical changes, and other immunological aspects such as CD4+ T cells. The viral load in peripheral blood among two groups after receiving antiretroviral treatment (ARV) was also measured.
The cohort study was carried out in Dr Kariadi Hospital Semarang from January 2012 to June 2013 on 52 HIV patients and 40 TB-HIV patients who were observed for one year of antiretroviral and antituberculosis treatment. Five HIV patients and 5 TB-HIV patients died during the studies. The number of Tregs (CD4+CD25+) was assessed by flowcytometer (FACS), viral load was done by measuring HIV-RNA in peripheral blood of patients with HIV and TB-HIV after one year antiretroviral treatment.
The results indicate that the number of Tregs was significantly different between the two groups at the beginning of treatment (p = 0.001). The number of Treg was increased in the HIV patients and was decreased in the TB-HIV patients after antiretroviral treatment. However, there was inverse relationship between the number of Tregs (CD4+ CD25+) and CD4+ T cells. There was positive relationship between the number of Tregs with viral load of HIV patients and TB-HIV patients after antiretroviral Treatment.
In conclusions, the number of Tregs (CD4 + CD25 +) may be suggested as a factor to determine progression of the diseases beside CD4+ T cells and viral load.Keywords
Full Text:
PDFReferences
Indonesian Ministry of Health, AIDS National Data June 2013. Jakarta.
Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. Aids. 2003;17(13):1881-8.
Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. The Journal of Immunology. 2002;169(6):3400-6.
Simonetta F, Bourgeois C. CD4+ FOXP3+ Regulatory T-Cell Subsets in Human Immunodeficiency Virus Infection. Frontiers in immunology. 2013;4.
Kataoka H, Takahashi S, Takase K, Yamasaki S, Yokosuka T, Koike T, et al. CD25+CD4+ regulatory T cells exert in vitro suppressive activity independent of CTLA-4. International immunology. 2005;17(4):421-7.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature immunology. 2003;4(4):330-6.
Kolte L, Gaardbo J, Skogstrand K, Ryder L, Ersb√∏ll AKr, Nielsen S. Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus‚ A infected patients after 5 years of highly active anti‚ Antiretroviral therapy may be due to increased thymic production of naive Tregs. Clinical & Experimental Immunology. 2009;155(1):44-52.
Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, et al. CD25+ CD4+ regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4+ and CD8+ HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. The Journal of experimental medicine. 2004;200(3):331-43.
Montes M, Lewis DE, Sanchez C, de Castilla DL, Graviss EA, Seas C, et al. Foxp3+ regulatory T cells in antiretroviral-naive HIV patients. Aids. 2006;20(12):1669-71.
Guihot Al, Tubiana R, Breton G, Marcelin A-Gv, Samri A, Assoumou L, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. Aids. 2010;24(4):614-7.
Weiss L, Donkova-Petrini V, Caccavelli L, Balbo Ml, Carbonneil Cd, Levy Y. Human immunodeficiency virus‚ Äìdriven expansion of CD4+ CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood. 2004;104(10):3249-56.
Aandahl EM, Michalsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. Journal of virology. 2004;78(5):2454-9.
Tsunemi S, Iwasaki T, Imado T, Higasa S, Kakishita E, Shirasaka T, et al. Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients. Aids. 2005;19(9):879-86.
Chun T-W, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (London, England). 2010;24(18):2803.
Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, et al. HIV-1‚ Ä driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood. 2006;108(12):3808-17.
Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. The Journal of Immunology. 2005;174(7):4407-14.
Thorborn G, Pomeroy L, Isohanni H, Perry M, Peters B, Vyakarnam A. Increased sensitivity of CD4+ T-effector cells to CD4+CD25+ Treg suppression compensates for reduced Treg number in asymptomatic HIV-1 infection. PloS one. 2010;5(2):e9254.
Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Shafer KP, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. Journal of Infectious Diseases. 2008;197(1):126-33.
Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104(4):942-7.
Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27(3):406-16.
Weiss L, Piketty C, Assoumou L, Didier Cl, Caccavelli L, Donkova-Petrini V, et al. Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy. PloS one. 2010;5(7):e11659.
Braithwaite RS, Kozal MJ, Chang CCH, Roberts MS, Fultz SL, Goetz MB, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS (London, England). 2007;21(12):1579.
Imami N, Westrop SJ, Grageda N, Herasimtschuk AA. Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses. Frontiers in immunology. 2013;4.
Kaufmann GR FH, Ledergerber B, Perrin L, Opravil M,et al. Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to !500 Cells/mL in HIV Type 1–Infected Individuals Receiving Potent Antiretroviral Therapy. . Clinical Infectious Diseases. 2005;;41::361–72.
Chun T-W, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (London, England). 2010;24(18):2803.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.